本页面由Tiger Trade Technology Pte. Ltd.提供服务

Inozyme Pharma

4.00
0.0000
成交量:- -
成交额:583.41万
市值:2.60亿
市盈率:-2.38
高:4.00
开:4.00
低:4.00
收:4.00
52周最高:6.24
52周最低:0.7210
股本:6,491.57万
流通股本:3,014.82万
量比:- -
换手率:- -
股息:- -
股息率:- -
每股收益(TTM):-1.6822
每股收益(LYR):-1.6243
净资产收益率:-141.69%
总资产收益率:-48.45%
市净率:8.17
市盈率(LYR):-2.46

数据加载中...

2023/05/09

重要事件披露

8-K - Current report
2023/05/09

季度报告

10-Q - Quarterly report [Sections 13 or 15(d)]
2023/04/04

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2023/03/22

重要事件披露

8-K - Current report
2023/03/22

年度报告

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2023/03/22

员工持股计划

S-8 - Securities to be offered to employees in employee benefit plans
2023/03/10

重要事件披露

8-K - Current report
2023/03/07

超过5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2023/02/16

重要事件披露

8-K - Current report
2023/02/14

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/02/14

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/02/14

超过5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2023/02/14

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/02/13

超过5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2023/02/10

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/02/09

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/12/08

重要事件披露

8-K - Current report
2022/12/08

重要事件披露

8-K - Current report
2022/11/10

重要事件披露

8-K - Current report
2022/11/10

季度报告

10-Q - Quarterly report [Sections 13 or 15(d)]